Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ: NEO )

14.42 +0.51 (+3.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Recap: NeoGenomics Q2 Earnings
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01),... 
Via Benzinga
Recap: NeoGenomics Q1 Earnings
Shares of NeoGenomics (NASDAQ:NEO) decreased 0.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 100.00% year... 
Via Benzinga
NeoGenomics Announces Board of Directors' Transition
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT.... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people... 
Via Benzinga
Why Guardant Health Is Down More Than 14% Friday
Investors aren't fans of an acquisition the diagnostics company is rumored to be considering. 
Via The Motley Fool
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar... 
Via Benzinga
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
NeoGenomics, inc (NEO) Q2 2021 Earnings Call Transcript
NEO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NeoGenomics Q2 Earnings Helped By Higher Test Volume; Backs FY21 Guidance
NeoGenomics Inc (NASDAQ: NEO) reported Q2 revenue of $122 million, +40% Y/Y, beating the consensus of $118.16 million. Clinical Services revenue of $101 million... 
Via Benzinga
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
Second-Quarter 2021 Results and Highlights: - Consolidated revenue increased 40% to $122 million - Clinical Services revenue increased 37% to $101 million - Pharma Services revenue increased 55% to $20... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
- Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market FT. MYERS, FL / ACCESSWIRE / June 18, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Earnings Scheduled For August 6, 2021
Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million.... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had... 
Via Benzinga
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
These 7 Medical Stocks Are Breaking Down — The Sell Rule You Should Know
Former high-flyers Dexcom and Tandem Diabetes are among seven health care stocks breaking down right now, according to MarketSmith.com. 
Via Investor's Business Daily
NeoGenomics To Participate In The Bank of America 2021 Health Care Conference
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Neogenomics Inc (NEO) Q1 2021 Earnings Call Transcript
NEO earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NeoGenomics Exercises Option To Acquire Remaining Stake In Inivata For $390M
NeoGenomics Inc (NASDAQ: NEO) has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in... 
Via Benzinga
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
NeoGenomics Reports 9% Revenue Growth to $116 Million in the First Quarter
First-Quarter 2021 Results and Highlights: - Consolidated revenue increased 9% to $116 million - Clinical Services revenue increased 4% to $96 million - Pharma Services revenue increased 46% to $19... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Cramer Advises Viewers On JetBlue Airways, MP Materials And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would own JetBlue Airways Corporation (NASDAQ: JBLU). If it drops $2, he would buy more. Big Lots, Inc. (... 
Via Benzinga
NeoGenomics to Participate in the 20th Annual Needham Virtual Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.